Literature DB >> 2147908

Dose-dependent effects of verapamil and nifedipine on in vivo platelet function in normal volunteers.

K Winther1, C M Jespersen, B Rydberg, G Thamsborg, T Hedner.   

Abstract

The effects of 1 week of treatment with low and moderate doses of verapamil or nifedipine upon platelet function has been studied in 12 healthy volunteers. The ex vivo platelet aggregation threshold for ADP or adrenaline was not altered by verapamil or nifedipine. The plasma concentrations of beta-thromboglobulin and platelet factor 4 were significantly reduced by low but not by moderate doses of verapamil and nifedipine. Low doses of verapamil and nifedipine inhibit in vivo platelet activity in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147908     DOI: 10.1007/bf00315114

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

2.  Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists.

Authors:  G Muiesan; E Agabiti-Rosei; G Romanelli; M L Muiesan; M Castellano; M Beschi
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

3.  The effects of nifedipine on platelet aggregation and plasma 6-keto-PGF1 alpha, and its interaction with indomethacin.

Authors:  M B Murphy; M A Orchard; E L Conway; S E Barrow
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Effect of metoprolol and propranolol on platelet aggregation and cAMP level in hypertensive patients.

Authors:  K Winther; J B Knudsen; J Gormsen; J Jensen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  Blood platelets in human essential hypertension.

Authors:  F De Clerck
Journal:  Agents Actions       Date:  1986-08

6.  Elevation of platelet factor four in acute myocardial infarction: measurement by radioimmunoassay.

Authors:  R I Handin; M McDonough; M Lesch
Journal:  J Lab Clin Med       Date:  1978-02

7.  Plasma concentrations of platelet-specific proteins in different stages of essential hypertension: interactions between platelet aggregation, blood lipids and age.

Authors:  J Yamanishi; H Sano; K Saito; Y Furuta; H Fukuzaki
Journal:  Thromb Haemost       Date:  1985-08-30       Impact factor: 5.249

8.  Platelets and hypertension.

Authors:  P Erne; T J Resink; E Bürgisser; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

9.  Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.

Authors:  C R Jones; F Pasanisi; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

10.  Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.

Authors:  E Glusa; J Bevan; S Heptinstall
Journal:  Thromb Res       Date:  1989-07-15       Impact factor: 3.944

View more
  2 in total

Review 1.  A comparative review of the adverse effects of calcium antagonists.

Authors:  H T Dougall; J McLay
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

2.  Postinfarct treatment with verapamil. Effect of verapamil in patients with hypertension.

Authors:  J F Hansen
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.